How to Help Your Patients Find Sronyx 28 Day in Stock: A Provider's Guide

Your Patients Can't Find Sronyx 28 Day — Here's How You Can Help

If your phone has been ringing with patients asking about Sronyx 28 Day, you already know the situation: Mayne Pharma discontinued the product in early 2025, and there's no remaining stock. Your patients are frustrated, confused, and in some cases running out of their birth control with no clear next step.

As a prescriber, you're in a unique position to smooth this transition. This guide covers the current availability landscape, practical steps you can take, equivalent alternatives, and workflow tips to manage the transition efficiently.

Current Availability: What You Need to Know

Sronyx 28 Day (levonorgestrel 0.1 mg / ethinyl estradiol 0.02 mg) has been permanently discontinued by Mayne Pharma. No supply exists at any wholesaler or pharmacy as of 2026. Prescriptions written for Sronyx will not be fillable.

However, multiple therapeutically equivalent products remain available. These contain the identical active ingredients at identical doses in the same 21/7 monophasic format:

• Vienva (Exeltis)
• Aubra (Afaxys)
• Aviane (Teva)
• Lutera (Mayne Pharma — verify current availability)
• Falmina (Novel Laboratories)
• Larissia (Northstar Rx)
• Orsythia (Qualitest/Endo)

For the broader clinical context on this discontinuation, see our provider shortage briefing.

Why Patients Can't Find Sronyx 28 Day

Understanding the root cause helps you communicate effectively with patients:

• Permanent discontinuation: This is not a temporary backorder. Mayne Pharma has stopped production entirely.
• Single-source product: No other manufacturer produced a pill under the Sronyx name. When Mayne Pharma exited, the product ceased to exist.
• Demand shift: Thousands of patients transitioning simultaneously to alternatives created brief localized shortages of products like Vienva and Aubra. Most of these have resolved, but availability can still be uneven at individual pharmacy locations.
• Patient brand loyalty: Many patients specifically request Sronyx by name, not realizing that multiple equivalent products exist. Education is key.

What Providers Can Do: 5 Steps

Step 1: Prescribe by Generic Name

Write prescriptions for "levonorgestrel/ethinyl estradiol 0.1 mg/0.02 mg tablets" rather than specifying a brand. This gives the dispensing pharmacy flexibility to fill with whichever equivalent product they have on hand. Ensure the prescription does not include a DAW (Dispense as Written) designation, which would prevent substitution.

Step 2: Check Availability Before Prescribing

Use Medfinder for Providers to check real-time availability at pharmacies near your patient. This takes seconds and can prevent the frustrating cycle of patient → pharmacy → callback → new pharmacy → callback that wastes everyone's time.

Step 3: Proactively Notify Affected Patients

If your EHR can generate a report of patients currently prescribed Sronyx, consider a batch communication (patient portal message, phone outreach, or letter) informing them of the change. Include:

• That Sronyx has been permanently discontinued
• That equivalent alternatives exist with the same active ingredients
• Instructions to call for a new prescription or schedule a brief telehealth visit
• A link to patient-facing resources like our alternatives guide

Step 4: Educate and Reassure

Patients who have been on Sronyx for years may be anxious about any change. Key reassurance points:

• The replacement contains exactly the same hormones at the same doses
• Only inactive ingredients (fillers, dyes, binders) differ between brands
• Most patients notice zero difference in effectiveness or side effects
• Mild breakthrough bleeding in the first 1-2 cycles is possible but self-resolving
• Contraceptive efficacy is maintained when switching between equivalent formulations

Step 5: Follow Up After the Switch

Consider scheduling a brief follow-up (in-person or telehealth) at 2-3 months to check in on patients who switched. This demonstrates proactive care, catches the rare patient who has a tolerability issue with the new brand's inactive ingredients, and allows for early intervention if needed.

Alternative Considerations Beyond Direct Equivalents

For patients who use this transition as an opportunity to reconsider their contraceptive method entirely, options to discuss include:

• Other low-dose COCs: Levora (0.15/0.03), Lo Loestrin Fe (norethindrone/EE), or Yaz (drospirenone/EE) for patients who want a different progestin
• Long-acting reversible contraceptives (LARCs): Hormonal IUDs (Mirena, Kyleena, Liletta), copper IUD (Paragard), or implant (Nexplanon)
• Non-daily methods: Vaginal ring (NuvaRing, Annovera) or patch (Xulane)

Workflow Tips for Your Practice

• Update EHR favorites: Remove Sronyx from any quick-pick lists and replace with available alternatives (Vienva, Aviane, or the generic name)
• Create a staff FAQ: Equip your MA/nurse team with a brief talking point sheet so they can field initial patient calls without requiring provider intervention
• Bookmark availability tools: Add medfinder.com/providers to your browser bookmarks for quick pharmacy stock checks
• Set up refill protocol: Work with your practice's refill line to automatically convert incoming Sronyx refill requests to the equivalent generic

Final Thoughts

The Sronyx 28 Day discontinuation is a manageable clinical transition. The identical formulation is available under multiple brand names, insurance coverage is robust, and patient outcomes should be unchanged. The primary challenge is communication and logistics — getting the right prescription to the right pharmacy with the least friction.

Leveraging tools like Medfinder for Providers, prescribing by generic name, and proactively reaching out to affected patients will help your practice navigate this transition smoothly.

For additional clinical context, see our Sronyx shortage briefing for prescribers. For patient-facing resources to share, see our guides on Sronyx alternatives and saving money on Sronyx alternatives.